A Study of SHR-A2102 Versus Investigator's Choice of Chemotherapy in Patients With Platinum-based Chemotherapy and PD-(L)1 Inhibitor Treatment Failed Recurrent or Metastatic Cervical Cancer

A Study of SHR-A2102 Versus Investigator's Choice of Chemotherapy in Patients With Platinum-based Chemotherapy and PD-(L)1 Inhibitor Treatment Failed Recurrent or Metastatic Cervical Cancer is a phase 3 interventional study registered as NCT07418749, led by Suzhou Suncadia Biopharmaceuticals, and recruiting on the registry. Official title: An Open-label, Randomised, Controlled, Multicenter, Phase III Study of SHR-A2102 Versus Investigator's Choice of Chemotherapy in Patients With Platinum-based Chemotherapy and PD-(L)1 Inhibitor Treatment Failed Recurrent or Metastatic Cervical Cancer. Planned enrolment is 398 participants (estimated). The study started in 2026-03-30 and primary completion is expected in 2027-12. No results have been posted on ClinicalTrials.gov.